200
Participants
Start Date
September 23, 2016
Primary Completion Date
August 27, 2019
Study Completion Date
August 27, 2019
Rovalpituzumab tesirine
Dexamethasone
Dexamethasone will be provided through a participant's local prescription by Investigator or other provider (i.e., dexamethasone will not be provided by the Sponsor).
Weill Cornell Medical College /ID# 155418, New York
Roswell Park Comprehensive Cancer Center /ID# 162015, Buffalo
Johns Hopkins University /ID# 155412, Baltimore
Virginia Cancer Specialists /ID# 162006, Fairfax
Greenville Hospital System /ID# 155427, Greenville
Emory University Hospital /ID# 155417, Atlanta
University of Florida - Archer /ID# 155414, Gainesville
University of Kentucky Chandler Medical Center /ID# 155423, Lexington
Univ Hosp Cleveland /ID# 155410, Cleveland
Washington University-School of Medicine /ID# 155425, St Louis
Mary Crowley Cancer Research /ID# 162014, Dallas
University of Texas MD Anderson Cancer Center /ID# 155413, Houston
Univ of Colorado Cancer Center /ID# 155415, Aurora
Sarah Cannon Research Institute at HealthONE - Denver /ID# 155420, Denver
Banner MD Anderson Cancer Ctr /ID# 155424, Gilbert
Mayo Clinic - Scottsdale /ID# 155419, Scottsdale
University of New Mexico /ID# 205054, Albuquerque
Cedars-Sinai Medical Center - West Hollywood /ID# 155428, West Hollywood
University of California, Los Angeles /ID# 155429, Los Angeles
Oregon Health and Science University /ID# 162011, Portland
Northwest Cancer Specialists, P.C. /ID# 155431, Vancouver
Univ California, San Francisco /ID# 155409, San Francisco
Moffitt Cancer Center /ID# 170220, Tampa
Massachusetts General Hospital /ID# 155411, Boston
Dana-Farber Cancer Institute /ID# 171044, Boston
Mayo Clinic - Rochester /ID# 155416, Rochester
Rutgers Cancer Institute of NJ /ID# 162010, New Brunswick
Duke University Medical Center /ID# 155421, Durham
Texas Oncology - Forth Worth /ID# 162045, Fort Worth
University of Utah /ID# 155426, Salt Lake City
Lead Sponsor
AbbVie
INDUSTRY